Choice of antibody immunotherapy influences cytomegalovirus viremia in simultaneous pancreas-kidney transplant recipients

被引:33
作者
Huurman, VAL
Kalpoe, JS
Van de Linde, P
Vaessen, N
Ringers, J
Kroes, ACM
Roep, BO
De Fijter, JW
机构
[1] Leiden Univ, Med Ctr, Dept Nephrol, NL-2300 RC Leiden, Netherlands
[2] Leiden Univ, Med Ctr, Dept Surg, NL-2300 RC Leiden, Netherlands
[3] Leiden Univ, Med Ctr, Dept Med Microbiol, NL-2300 RC Leiden, Netherlands
[4] Leiden Univ, Med Ctr, Dept Immunohaematol & Blood Transfus, NL-2300 RC Leiden, Netherlands
关键词
D O I
10.2337/diacare.29.04.06.dc05-1647
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE - Simultaneous pancreas-kidney (SPK) transplantation in type 1. diabetic patients requires immunotherapy against allo- and autoreactive T-cells. Cytomegalovirus (CMV) infection is a major cause for morbidity after transplantation and is possibly related to recurrent autoimmunity. In this study, we assessed the pattern of CMV viremia in SPK transplant recipients receiving either antithymocyte globulin (ATG) or anti-CD25 (daclizumab) immunosuppressive induction therapy. RESEARCH DESIGN AND METHODS - We evaluated 36 SPK transplant recipients from a randomized cohort that received either ATG or daclizumab as induction therapy. Patients at risk for CMV infection received oral prophylactic ganciclovir therapy. The CMV DNA level in plasma was measured for at least 180 days using a quantitative real-time PCR. Recipient peripheral blood mononuclear cells were cross-sectionally HLA tetramer-stained for CMV-specific CD8(+) T-cells. RESULTS - Positive CMV serostatus in donors was correlated with a higher incidence of CMV viremia than negative serostatus. In patients at risk, daclizumab induction therapy significantly prolonged CMV-free survival. CMV viremia occurred earlier and was more severe in patients T-cell with rejection episodes than in patients without rejection episodes. CMV-specific CD8(+) cell counts were significantly lower in patients developing CMV viremia than in those who did not. CONCLUSIONS - Despite their comparable immunosuppressive potential, daclizumab is safer than ATG regarding CMV infection risk in SPK transplantation. ATG-treated rejection episodes are associated With earlier and more severe infection. Furthermore, high CMV-specific tetramer counts reflect antiviral immunity rather than concurrent viremia because they imply low viremic activity. These findings may prove valuable in the discussion on both safety of induction therapy and recurrent autoimmunity in SPK and islet transplantation.
引用
收藏
页码:842 / 847
页数:6
相关论文
共 34 条
[1]   Comparison of daclizumab, an interleukin 2 receptor antibody, to anti-thymocyte globulin-Fresenius induction therapy in kidney transplantation [J].
Abou-Jaoude, MM ;
Ghantous, I ;
Almawi, WY .
MOLECULAR IMMUNOLOGY, 2003, 39 (17-18) :1083-1088
[2]  
[Anonymous], 2000, Diabetes Care, V23, P117
[3]   Antilymphocyte/thymocyte globulin for graft versus host disease prophylaxis: efficacy and side effects [J].
Bacigalupo, A .
BONE MARROW TRANSPLANTATION, 2005, 35 (03) :225-231
[4]   Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation [J].
Becker, BN ;
Becker, YT ;
Leverson, GE ;
Simmons, WD ;
Sollinger, HW ;
Pirsch, JD .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2002, 39 (05) :1088-1095
[5]   Multicenter survey of daclizumab induction in simultaneous kidney-pancreas transplant recipients [J].
Bruce, DS ;
Sollinger, HW ;
Humar, A ;
Sutherland, DER ;
Light, JA ;
Kaufman, DB ;
Alloway, RR ;
Lo, A ;
Stratta, RJ .
TRANSPLANTATION, 2001, 72 (10) :1637-1643
[6]   Prospective, randomized trial of the effect of antibody induction in simultaneous pancreas and kidney transplantation: Three-year results [J].
Burke, GW ;
Kaufman, DB ;
Millis, JM ;
Gaber, AO ;
Johnson, CP ;
Sutherland, DER ;
Punch, JD ;
Kahan, BD ;
Schweitzer, E ;
Langnas, A ;
Perkins, J ;
Scandling, J ;
Concepcion, W ;
Stegall, MD ;
Schulak, JA ;
Gores, PF ;
Benedetti, E ;
Danovitch, G ;
Henning, AK ;
Bartucci, MR ;
Smith, S ;
Fitzsimmons, WE .
TRANSPLANTATION, 2004, 77 (08) :1269-1275
[7]   Randomized comparison of triple therapy and antithymocyte globulin induction treatment after simultaneous pancreas-kidney transplantation [J].
Cantarovich, D ;
Karam, G ;
Giral-Classe, M ;
Hourmant, M ;
Dantal, J ;
Blancho, G ;
Le Normand, L ;
Soulillou, JP .
KIDNEY INTERNATIONAL, 1998, 54 (04) :1351-1356
[8]   Midterm results of a prospective randomized comparison of two different rabbit-antithymocyte globulin induction therapies after heart transplantation [J].
De Santo, LS ;
Della Corte, A ;
Romano, G ;
Amarelli, C ;
Onorati, F ;
Torella, M ;
De Feo, M ;
Marra, C ;
Maiello, C ;
Giannolo, B ;
Casillo, R ;
Ragone, E ;
Grimaldi, M ;
Utili, R ;
Cotrufo, M .
TRANSPLANTATION PROCEEDINGS, 2004, 36 (03) :631-637
[9]   Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation [J].
Emery, VC ;
Sabin, CA ;
Cope, AV ;
Gor, D ;
Hassan-Walker, AF ;
Griffiths, PD .
LANCET, 2000, 355 (9220) :2032-2036
[10]   Infection in organ-transplant recipients [J].
Fishman, JA ;
Rubin, RH .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (24) :1741-1751